<p>Theraclion SA reported a turnover of €1.19 million for 2025, representing a 44% increase compared to €830,000 in the previous year. The company recorded sales growth in several segments, including a 30% rise in sales of Pay per Use (PPU) and consumables to €626,000, and a 10% increase in sales of services to €218,000. Merchandise sales in China decreased by 22% to €348,000, while sales of Sonovein® systems reached €379,000. The company also noted a credit note for Echopulse of €680,000. As of December 31, 2025, Theraclion’s available cash stood at €3.4 million, further supplemented by a €0.9 million reimbursement from the French tax authorities in January 2026. The current financial outlook extends to the end of May 2026, with the company taking steps to secure additional funding to support its business plan and growth objectives. Theraclion highlighted progress in clinical validation, regulatory milestones in the United States, Europe, and China, and increased commercial activity, including new contracts and expansion of its prospect list. The next financial results are scheduled for release on April 16, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theraclion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260129473447) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Reuters

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Atara Biotherap

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Theraclion Reports 44% Turnover Growth and Expands Pay per Use Model in 2025